RVTY Revvity
- 109.260
- +0.920+0.85%
- 109.260
- 0.0000.00%
Revvity News
Optimism Around Revvity (NYSE:RVTY) Delivering New Earnings Growth May Be Shrinking as Stock Declines 4.4% This Past Week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But its virtually certain that sometimes you will buy stocks that fall
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
Revvity to Present at Goldman Sachs Global Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. ET in Miami, FL.Prahlad Sin
Revvity Currently Up 10 Consecutive Days, On Pace for Longest Winning Streak Since June 2021 -- Data Talk
Revvity, Inc. (RVTY) is currently at $113.62, up $0.39 or 0.34% --Would be highest close since Sept. 1, 2023, when it closed at $116.92 --Currently up 12 of the past 13 days --Currently up 10 conse
Form 144 | Revvity(RVTY.US) Officer Proposes to Sell 1.86 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 15, $Revvity(RVTY.US)$ Officer Tereau Daniel R intends to sell 17,291 shares of its common stock on May 15, with a total market value of approximately $1.86 million. Sou
Revvity, Inc. (NYSE:RVTY) Not Flying Under The Radar
With a price-to-earnings (or "P/E") ratio of 70.5x Revvity, Inc. (NYSE:RVTY) may be sending very bearish signals at the moment, given that almost half of all companies in the United States have P/E ratios under 17x and even P/E's lower than 9x are not unusual.
Revvity | 10-Q: Quarterly report
Goldman's Top 50 Weak Balance Sheet Stocks
Goldman Sachs analysts listed 50 stocks constituents of their “weak balance sheet” basket.
Revvity Price Target Raised to $127.00/Share From $126.00 by Baird
Revvity Price Target Raised to $127.00/Share From $126.00 by Baird
4 Analysts Have This To Say About Revvity
During the last three months, 4 analysts shared their evaluations of Revvity (NYSE:RVTY), revealing diverse outlooks from bullish to bearish.In the table below, you'll find a summary of their recent r
Revvity Is Maintained at Buy by TD Cowen
Revvity Is Maintained at Buy by TD Cowen
TD Cowen: Maintaining the Revvity (RVTY.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $123.00 to $130.00.
TD Cowen: Maintaining the Revvity (RVTY.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $123.00 to $130.00.
TD Cowen Maintains Buy on Revvity, Raises Price Target to $130
TD Cowen analyst Dan Brennan maintains Revvity (NYSE:RVTY) with a Buy and raises the price target from $123 to $130.
Revvity Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/30/2024 23.81% TD Cowen $123 → $130 Maintains Buy 02/02/2024 4.76% Stifel $95 → $110 Maintains Hold 02/
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), DocGo (DCGO) and Revvity (RVTY)
Bernstein Adjusts Price Target on Revvity to $123 From $125, Keeps Outperform Rating
Revvity (RVTY) has an average rating of outperform and a price target range of $105 to $162, according to analysts polled by Capital IQ. Price: 105.00, Change: -0.02, Percent Change: -0.02
Revvity (RVTY) Receives a Hold From Barclays
Revvity Inc (RVTY) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations With ...
Earnings Call Summary | Revvity(RVTY.US) Q1 2024 Earnings Conference
The following is a summary of the Revvity, Inc. (RVTY) Q1 2024 Earnings Call Transcript:Financial Performance:Revvity reported Q1 revenues of $650 million, a decrease of 3% in organic revenue.The comp
Revvity Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Revvity Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Analysis
Price Target
No Data
